Cellectis Stock Price, News & Analysis

Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE base editors (TALEB) and non-viral gene insertion at the European Society of Cell and Gene Therapy 31st annual congress in Roma, Italy, from October 22-25, 2024. Two posters will be showcased:

1. 'Controlling C-to-T editing with TALE base editors' by Alexandre Juillerat, Ph.D., on October 24. This study enhances understanding of TALEB and allows for the design of efficient and specific tools potentially compatible with therapeutic applications.

2. 'Circular Single-Stranded DNA Enables Efficient TALEN-Mediated Gene Insertion in Long Term HSC' by Julien Valton, Ph.D., also on October 24. This research demonstrates that circularizing ssDNA increases gene insertion rates in long-term HSCs and may enhance their engraftment capacity in preclinical murine models, advancing non-viral gene therapy.

Cellectis (CLLS) has released its monthly information on share capital and voting rights as of September 30, 2024. The company reported a total of 100,093,873 shares in the capital and 88,569,683 voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.

Cellectis is listed on the Euronext Growth market with the ISIN code FR0010425595. For additional information, investors and media can contact the company's designated representatives, including the Director of Communications and the Chief of Staff to the CEO. The Interim Chief Financial Officer is available for investor relations inquiries.

Cellectis (CLLS) has released its monthly update on share capital and voting rights as of August 31, 2024. The company reported a total of 100,093,635 shares in the capital and 88,029,440 voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority. Cellectis is listed on the Euronext Growth market under the ISIN code FR0010425595.

For investors seeking further information, Cellectis has provided contact details for media and investor relations inquiries. This regular disclosure helps maintain transparency and keeps shareholders informed about the company's capital structure.

Cellectis, a clinical-stage biotechnology company, has published a scientific article in Science Advances showcasing promising pre-clinical results for treating triple-negative breast cancer (TNBC) using TALEN®-edited MUC1 CAR T-cells. The study demonstrates that multi-armored CAR T-cells, engineered with PD1KO, tumor-specific IL12 release, and TGFBR2KO attributes, showed enhanced cytotoxic activity against TNBC in mouse models.

Notably, intratumoral treatment effectively reduced both local and distant tumors using low doses of the engineered CAR T-cells, suggesting potential efficacy against metastasis. The research highlights the capabilities of multiplex editing in improving both efficacy and safety of CAR T-cell therapies for solid tumors, offering hope for advanced-stage TNBC patients with treatment options.

Cellectis (NASDAQ: CLLS) has published an article in Molecular Therapy showcasing their innovative SMART DUAL CAR T-cell approach for treating solid tumors. Using TALEN® gene editing technology, Cellectis has developed allogeneic CAR T-cells that express:

1. A constitutive CAR targeting FAP+ cancer-associated fibroblasts (CAFs) in solid tumors
2. An inducible CAR, expressed only in the presence of FAP+ CAFs, targeting mesothelin

This strategy aims to overcome challenges in solid tumor treatment, including low T-cell infiltration, immunosuppressive microenvironment, and on-target off-tumor toxicity. In mice models, these SMART Dual CAR T-cells efficiently infiltrated and targeted triple-negative breast tumors without observable off-tumor toxicity.

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has appointed Dr. Adrian Kilcoyne as its new Chief Medical Officer. Dr. Kilcoyne brings extensive experience in oncology and cell therapy from his previous roles at Celularity, Humanigen, AstraZeneca, and Celgene. His appointment is expected to strengthen Cellectis' clinical development efforts in advancing their pipeline of next-generation CAR T-cell therapies.

Dr. Kilcoyne's background includes a medical degree from Trinity College, Dublin, training in Gynecological Oncology and Public Health Medicine, and an MBA. He replaces Dr. Mark Frattini, who is departing to pursue other opportunities. The company's CEO, André Choulika, expressed confidence in Dr. Kilcoyne's ability to contribute to Cellectis' mission of providing transformative UCART therapies to patients with significant unmet medical needs.

Cellectis provided its financial results for Q2 2024, reporting a cash position of $273 million as of June 30, 2024, and a cash runway projection into 2026. Key highlights include:

Pipeline Updates: UCART22 received ODD from both the FDA and the European Commission for ALL treatment, and RPDD from the FDA. CLLS52 (alemtuzumab) also received ODD from the FDA for ALL treatment.

Financial Performance: Consolidated revenues and other income increased to $16 million for the six months ended June 30, 2024, compared to $5.6 million for the same period in 2023. Consolidated net loss reduced to $19.6 million from $41.8 million, reflecting better financial management and increased revenues.

Partnerships: Cellectis announced a $140 million investment from AstraZeneca, which now owns approximately 44% of Cellectis' share capital.

Research: A significant publication in Nature Communications on their non-viral gene therapy approach for SCD.

Cellectis (CLLS) has released its monthly share capital and voting rights information as of July 31, 2024, in compliance with French financial market regulations. The report indicates that the total number of shares in the capital is 100,093,635, while the total number of voting rights stands at 88,029,164. This information is important for investors to understand the company's ownership structure and potential voting power distribution.

The press release provides contact details for media and investor relations, including Pascalyne Wilson (Director of Communications) and Arthur Stril (Interim Chief Financial Officer). This transparency in reporting and accessibility to company representatives demonstrates Cellectis' commitment to maintaining open communication channels with stakeholders and complying with regulatory requirements.

Cellectis (NASDAQ: CLLS) announced that the FDA has granted Orphan Drug Designation (ODD) to CLLS52 (alemtuzumab), used in the lymphodepletion regimen for UCART22 in the BALLI-01 clinical trial for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The addition of alemtuzumab to the fludarabine and cyclophosphamide regimen has shown sustained lymphodepletion and higher UCART22 cell expansion, leading to greater clinical activity.

Cellectis invented the combination of CD52 knockout UCART cells with a lymphodepleting regimen containing an anti-CD52 antibody. The CD52 knockout aims to make UCART products resistant to alemtuzumab. ODD status may help expedite and reduce costs for development, approval, and commercialization of CLLS52 for ALL treatment.